Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention

NCT07318103 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Fluid Retention Caused by Heart Failure

Interventions

DRUG: HRS-9057 injection set
DRUG: 5% Glucose Injection or 0.9% sodium chloride injection

Sponsor

Fujian Shengdi Pharmaceutical Co., Ltd.